Featured
-
-
Article
| Open AccessImpact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients
- S. G. Larsen
- , M. A. Goscinski
- & H. Sorbye
-
Comment |
A bacterial mutational footprint in colorectal cancer genomes
- Axel Rosendahl Huber
- , Cayetano Pleguezuelos-Manzano
- & Jens Puschhof
-
Brief Communication
| Open AccessGermline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank
- Jun Wei
- , Zhuqing Shi
- & Jianfeng Xu
-
Review Article
| Open AccessIDH mutation in glioma: molecular mechanisms and potential therapeutic targets
- Sue Han
- , Yang Liu
- & Chunzhang Yang
-
Article
| Open AccessOestrogen receptor status and survival in women with BRCA2-associated breast cancer
- Kelly Metcalfe
- , Henry T. Lynch
- & Steven A. Narod
-
Article
| Open AccessCandidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
- Darren R. Hodgson
- , Brian A. Dougherty
- & J. Carl Barrett
-
Genetics and Genomics
| Open AccessGNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi
- M J C Vader
- , M C Madigan
- & P A van der Velden
-
Genetics and Genomics
| Open AccessA comparative study of germline BRCA1 and BRCA2 mutation screening methods in use in 20 European clinical diagnostic laboratories
- Gillian Ellison
- , Andrew Wallace
- & Simon Patton
-
Genetics and Genomics
| Open AccessNon-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine
- Françoise Descotes
- , Norelyakin Kara
- & Alain Ruffion
-
Genetics and Genomics
| Open AccessSequencing of DICER1 in sarcomas identifies biallelic somatic DICER1 mutations in an adult-onset embryonal rhabdomyosarcoma
- Leanne de Kock
- , Barbara Rivera
- & William D Foulkes
-
Molecular Diagnostics
| Open AccessMutation status among patients with sinonasal mucosal melanoma and its impact on survival
- Moran Amit
- , Samantha Tam
- & Ehab Y Hanna
-
Genetics and Genomics
| Open AccessExtended RAS analysis and correlation with overall survival in advanced pancreatic cancer
- Michael Haas
- , Steffen Ormanns
- & Volker Heinemann
-
Molecular Diagnostics
| Open AccessSpecific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
- Robert P Jones
- , Paul A Sutton
- & Hassan Z Malik
-
Clinical Study
| Open AccessOverall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer
- Talia Golan
- , Tal Sella
- & Steven Gallinger
-
Genetics and Genomics
| Open AccessDevelopment of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients
- Umberto Malapelle
- , Clara Mayo de-Las-Casas
- & Giancarlo Troncone
-
Molecular Diagnostics
| Open AccessComparative mutational landscape analysis of patient-derived tumour xenografts
- Mariana Brait
- , Evgeny Izumchenko
- & David Sidransky
-
Clinical Study
| Open AccessA phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
- J J Yang
- , Q Zhou
- & Y L Wu
-
Clinical Study
| Open AccessEGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
- Yi-Long Wu
- , Lecia V Sequist
- & James Chih-Hsin Yang
-
Clinical Study
| Open AccessNon-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
- J L Kuiper
- , S M S Hashemi
- & E F Smit
-
Short Communication
| Open AccessOutcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
- Leendert H Zaaijer
- , Helena C van Doorn
- & Mieke Kriege
-
Review
| Open AccessPARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
- G E Konecny
- & R S Kristeleit
-
Short Communication
| Open AccessCessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
- Matteo S Carlino
- , Vito Vanella
- & Paolo A Ascierto
-
Clinical Study
| Open AccessOestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers
- Jon G Jonasson
- , Olafur A Stefansson
- & Laufey Tryggvadóttir
-
Short Communication
| Open AccessAn investigation of the association of genetic susceptibility risk with somatic mutation burden in breast cancer
- Bin Zhu
- , Anwesha Mukherjee
- & Nilanjan Chatterjee
-
Letter to the Editor
| Open AccessResponse to ‘Comments on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study’’
- Steven A Narod
-
Letter to the Editor
| Open AccessComment on ‘The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study’
- A V Paradiso
- , M Digennaro
- & D Sambiasi
-
Letter to the Editor
| Open AccessComment on ‘The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study’
- Bernard Friedenson
-
Mini Review
| Open AccessGenetic progression of Barrett’s oesophagus to oesophageal adenocarcinoma
- Eleanor M Gregson
- , Jan Bornschein
- & Rebecca C Fitzgerald
-
Translational Therapeutics
| Open AccessDual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
- Emiliano Cocco
- , Salvatore Lopez
- & Alessandro D Santin
-
Molecular Diagnostics
| Open AccessA UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma
- Michelle Chin I Lo
- , Anna Paterson
- & Laszlo Igali
-
Mini Review
| Open AccessMolecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies
- Shivshankari Rajkumar
- & Ian R Watson
-
Genetics and Genomics
| Open AccessMED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas
- Kati Kämpjärvi
- , Netta Mäkinen
- & Pia Vahteristo
-
Letter to the Editor
| Open AccessComment on ‘Wild-type APC prediction of poor prognosis in microsatellite-stable proximal colorectal cancer differs according to the age of onset’
- José Perea
- , María Arriba
- & Miguel Urioste
-
Mini Review
| Open AccessThe clinical implications of gene mutations in chronic lymphocytic leukaemia
- Davide Rossi
- & Gianluca Gaidano
-
Molecular Diagnostics
| Open AccessMimicking the tumour microenvironment of chronic lymphocytic leukaemia in vitro critically depends on the type of B-cell receptor stimulation
- Ans Rombout
- , Sofie Lust
- & Jan Philippé
-
Clinical Study
| Open AccessContribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis
- Xuan-Anh Phi
- , Sepideh Saadatmand
- & Nehmat Houssami
-
Clinical Study
| Open AccessClinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
- Petra Martin
- , Carolyn J Shiau
- & Natasha B Leighl
-
Clinical Study
| Open AccessPhase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
- E Elez
- , A Hendlisz
- & J Tabernero
-
-
Mini Review |
The development of PARP inhibitors in ovarian cancer: from bench to bedside
- Yvette Drew
-
Short Communication
| Open AccessAristolochic acid exposure in Romania and implications for renal cell carcinoma
- Robert J Turesky
- , Byeong Hwa Yun
- & Ghislaine Scelo
-
Clinical Study
| Open AccessHistopathological features of papillary thyroid carcinomas detected during four screening examinations of a Ukrainian-American cohort
- Tetiana I Bogdanova
- , Liudmyla Yu Zurnadzhy
- & Alina V Brenner
-
Clinical Study
| Open AccessClinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
- Fotios Loupakis
- , Roberto Moretto
- & Emilio Bria
-
Genetics and Genomics
| Open AccessOverexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma
- Chao Fan
- , Lu Chen
- & Jie Wu
-
Letter to the Editor
| Open AccessComment on: ‘KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.’ Variation in survival associated with proto-oncongenes is not evidence for effectiveness of lung metastasectomy
- Giuseppe Cardillo
- , Sahar Mokhles
- & Tom Treasure
-
Letter to the Editor
| Open AccessReply: Comment on ‘KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colo-rectal cancer’
- Stéphane Renaud
- , Pierre-Emmanuel Falcoz
- & Gilbert Massard
-
Letter to the Editor
| Open AccessReply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’
- Andrew Rowland
- , Mafalda M Dias
- & Michael J Sorich
-
Letter to the Editor
| Open AccessBRAF-mutated metastatic colorectal cancer between past and future
- Chiara Cremolini
- , Massimo Di Maio
- & Filippo Pietrantonio
-
Genetics and Genomics
| Open AccessTERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast
- Masayuki Yoshida
- , Reiko Ogawa
- & Shigeki Sekine